CorriXR Therapeutics
@CorriXR
Followers
22
Following
28
Media
15
Statuses
56
CorriXR is developing a #CRISPR gene editing platform to augment and improve current standard of care by genetically knocking out cancer drug resistance.
Newark, DE
Joined October 2023
Our preclinical study just published in Molecular Therapy Oncology shows that #CRISPR-Cas9-mediated NRF2 disruption restores chemosensitivity in head and neck and esophageal squamous cell carcinoma models - extending our previous findings in lung cancer. These results support our
businesswire.com
A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tu...
0
0
1
Congrats @CorriXR đ„łđ The #Delaware life science startup inked a deal to develop a pioneering inhalable therapy to treat lung cancer.
delawarebusinesstimes.com
The life science startup has inked a deal to develop a pioneering inhalable therapy to treat lung cancer with Merxin Ltd and InhaTarget Therapeutics.
0
2
2
Combining CorriXRâs groundbreaking #CRISPR platform with @inhatarget pulmonary #LNP drug delivery and @MRXdevices #inhalation device technology has the potential to reshape the landscape of #lungcancer treatment. #oncology #geneediting
businesswire.com
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a c...
0
0
1
CorriXR is using #geneediting to make tumor cells more responsive to chemotherapy and slow tumor growth. Our collaborators @GeneEditingDE just published a study in @MolTherapy #Oncology during đ«National Lung Cancer Awareness Month that sets a strong foundation for moving towards
businesswire.com
CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors,...
0
0
0
Congratulations to @RobertFerrisMD, a member of the CorriXR Clinical Advisory Board, on his election to the National Academy of Medicine!
Huge congratulations to @RobertFerrisMD, PhD, UNC Lineberger executive director and Samantha MeltzerâBrody, MD, MPH, executive dean of @UNC_SOM, on their election to the National AcademyâŻofâŻMedicine (@theNAMedicine) - one of the highest honors in health and medicine. đ Ferris
0
0
1
With a new COO and several consultants that were formerly as Spark Therapeutics, CorriXR plans on "rewriting the rules of cancer treatment."
bizjournals.com
CorriXR Therapeutics seeks $20 million in Series A funding. The firm has added a former Spark Therapeutics executive as CEO and brought in former Spark employees as consultants.
0
1
1
Itâs a whirlwind week! From @CorriXR board meeting to moderating @ChicagoFed Payments Conference to interviewing @blackstone CEO at @federalreserve community bank conference, woah! BTW, CorriXRâs CEO, Dr. Kmiec, has the most incredible swag in his office - so many patents!
1
1
4
Investing in Delawareâs innovators means investing in a healthier future. Newark-based CorriXR Therapeutics just received a $1M state grant to advance groundbreaking cancer gene-editing therapiesâsupporting local jobs, cutting-edge science, and life-saving treatments. Learn more:
newarkpostonline.com
A Newark-based biotherapeutics company has received a $1 million state grant to help it develop a new cancer treatment.
3
1
9
Exciting news! CorriXR has been selected to present our next generation treatment for solid tumors at the @LifeSciencesPA conference on Sept 25/26. #oncology #geneediting #CRISPR
0
0
0
Attending #BIO2025? Don't miss CorriXR's presentation on our next generation treatment for solid tumors on June 19 at 10:30 AM in Room 153B. #oncology #geneediting #CRISPR
0
0
1
COO Jan Case will present CorriXR's next generation treatment for solid tumors at #BIO2025 on June 19 at 10:30 AM in Room 153B. #oncology #geneediting #CRISPR
https://t.co/uhnjYTGA78
0
0
1
CorriXR Founder & CEO Eric Kmiec, Ph.D. will be presenting at the @BioNJ_Org BioPartnering Conference next week. #BioPartnering2025 #oncology #CRISPR #biotech #geneediting
0
1
2
Founder & CEO Eric Kmiec is presenting on the role #CRISPR can play in novel #oncology treatments at the @CrisprMedicine conference next week. We hope to see you there! #CRISPRMED25
0
2
4
Attending #CRISPRMED25? DM us to schedule a meeting with CorriXR Founder & CEO Eric B. Kmiec to learn more about our novel approach to treating solid tumors. #GeneEditing #CRISPR #oncology #biotech
0
0
1
0
0
1
Thrilled to announce that Jan Case has joined our team as COO. Her proven skills and expert guidance will help us achieve our goal of significantly improving the lives of people living with cancer. #CRISPR #geneediting #oncology #biotech
businesswire.com
CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors,...
0
0
0
CorriXR named one of 4 companies to watch in the accelerating #geneediting race by @Clarivate
@PharmaVoice #CRISPR #Oncology #biotech
https://t.co/VSDBGoBCKw
pharmavoice.com
A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.
0
1
0
CorriXR proudly announces the appointment of our founder Eric B Kmiec, Ph.D. as CEO. #genediting #CRISPR #oncology
businesswire.com
CorriXR Therapeutics, Inc., a leading biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, ha...
0
0
0